Patria Investments Limited Announces Launch of Initial Public Offering
News provided by
Share this article
Share this article
GRAND CAYMAN, Cayman Islands, Jan. 14, 2021 Patria Investments Limited ( Patria ), one of the leading private markets investment firms in Latin America, today announced that it has launched its initial public offering of 26,650,000 Class A common shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission ( SEC ). Patria is offering 16,650,000 Class A common shares and the selling shareholder, Blackstone PAT Holdings IV, L.L.C. is offering 10,000,000 Class A common shares. The estimated price range for the offering is US$14.00 and US$16.00 per Class A common share. Patria has applied to list its Class A common shares on the Nasdaq Global Select Market under the ticker symbol PAX. In connection with the offering, Patria and the selling shareholder expect to grant the underwriters a 30-day option to p
DBV Technologies S.A.: DBV Technologies Provides Update on Investigational Viaskin Peanut for Children Ages 4-11 Years
DBV Technologies Provides Update on Investigational Viaskin Peanut for Children Ages 4-11 Years
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the receipt of written responses from the U.S Food and Drug Administration (FDA) to questions provided in the Type A meeting request the Company submitted in October 2020. The Type A meeting request was submitted following the Company s receipt of a Complete Response Letter (CRL) in connection with its Biologics License Application (BLA) for Viaskin Peanut (DBV712), an investigational, non-invasive, once-daily epicutaneous patch to treat peanut allergy in children ages 4 to 11 years.
IPO Lockup Expiration Alert: Pandion Therapeutics (PAND)
Pandion Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients suffering from autoimmune diseases.
The company s lead product candidate is PT101, for which a phase 1a/2b clinical trial in ulcerative colitis is expected to start in mid-2021 and phase II clinical trial in systemic lupus erythematosus is expected to start in the second half 2021.
Also in the pipeline are a couple of compounds in pre-clinical testing like PT627 for the treatment of autoimmune disease, and PT002 and PT001, for the treatment of gastrointestinal and liver diseases.
Pandion Therapeutics made its debut on The Nasdaq Global Select Market on July 17, 2020, offering its shares at a price of $18 each and as mentioned above, the 180 day lockup period expires on January 13.
Lender Affirm Prices IPO Above Range to Raise $1.2 billion
Bloomberg 1/13/2021 Crystal Tse and Katie Roof
(Bloomberg) Affirm Holdings Inc., which provides installment loans to online shoppers, priced its U.S. initial public offering above its marketed range to raise $1.2 billion.
Popular Searches
In the first major U.S. technology listing this year, Affirm sold 24.6 million shares for $49 each, according to a statement on Wednesday, confirming an earlier Bloomberg News report. The San Francisco-based company had marketed the shares for $41 to $44 apiece, a range that it had raised Monday from $33 to $38.
The IPO gives Affirm a market value of $11.9 billion based on the outstanding shares listed in its filings with the U.S. Securities and Exchange Commission. The company’s fully diluted valuation, including options and restricted stock units, is about $15 billion.